Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2

Status

Terminated 3Unknown 2Recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Influenza Vaccines × Clear all
NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡